April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Role of Matrix Metalloproteinase-9 in LHBETATAG Retinal Tumor Growth
Author Affiliations & Notes
  • T. G. Murray
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Y. Pina
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • H. Boutrid
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • C. C. Cebulla
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • M. E. Jockovich
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida
  • Footnotes
    Commercial Relationships  T.G. Murray, None; Y. Pina, None; H. Boutrid, None; C.C. Cebulla, None; M.E. Jockovich, None.
  • Footnotes
    Support  ACS grant, NIH R01 EY013629, NIH center grant P30 EY014801 and by an unrestricted grant to the University of Miami from Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2039. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. G. Murray, Y. Pina, H. Boutrid, C. C. Cebulla, M. E. Jockovich; Role of Matrix Metalloproteinase-9 in LHBETATAG Retinal Tumor Growth. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2039.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Metalloproteinase-9 (MMP-9), a gelatinase, is essential for the extracellular matrix (ECM) remodeling required for tumor growth and angiogenesis. Macrophage secreted MMP-9 is essential for the growth of several tumors including ovarian and melanoma tumors. The purpose of this study is to analyze the role of MMP-9 in LHBETATAG retinal tumor growth.

Methods: : This study was approved by the IACUC and follows ARVO guidelines. Eyes were enucleated from twenty-four LHBETATAG mice at 4, 8, 12 and 16 weeks of age (n=6 for each age group). MMP-9 density was detected by immunohistochemistry. To analyze the role of MMP-9 on tumor growth, LHBETATAG MMP-9 knock-out mice were created through two cross breedings: (1) MMP-9 knock-out mice with LHBETATAG mice to produce an F1 generation, and (2) a dihybrid cross between F1 MMP-9 heterozygotes and LHBETATAGMMP-9 heterozygotes to produce retinal tumors with the MMP-9 knock-out gene. Gelatinase MMP-9 activity was measured using in situ zymography and immunohistochemistry.

Results: : Immunohistochemistry of MMP-9 gelatinase activity showed that MMP-9 expression increases with tumor progression, being most prevalent in advanced disease at 16 weeks of age (p=0.0339), confirming in situ zymography results. Tumor burden significantly increased by 12-fold in the MMP-9 knock-out mice. Homozygous MMP-9-(+)(+) mice presented with small-size tumors (0.72 mm2), whereas heterozygous MMP-9-(+)(-) mice presented tumors that increased in size by 305% (2.2 mm2) and homozygous MMP-9-(-)(-) mice presented large tumors that increased in size by 1153% (8.3 mm2).

Conclusions: : We have previously shown that MMP-9 activity increases with tumor progression. We have further shown that intraocular treatment with anti-angiogenic therapy reduces MMP-9 protein levels and activity and reduces tumor burden. In this study we demonstrate that depletion of MMP-9 results in increased tumor burden. We hypothesize that these unexpected results may be explained by: 1) MMP-9 gelatinase activity may be involved in tumor suppression through MI polarized macrophages, which cause tissue destruction; and 2) lack of MMP-9 results in overexpression of other gelatinases such as MMP-2.

Keywords: retina • tumors • immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.